340B Drug Pricing Program
Complete AHA Survey by May 28 on Drug Company 340B Data Policy Compliance
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party clearinghouse.
AHA urges Lilly to drop 340B claims-data policy, proposes neutral clearinghouse.
The House Committee on Ways and Means released draft bill text in advance of its planned May 20 markup.
The American Hospital Association expresses concern about Eli Lilly’s January 2026 claims-data policy and invites Lilly to work in good faith with the AHA and our 340B hospital members to find a better path forward than the cycle of escalation that has beset the 340B program in recent years.
AHA pushes back on WSJ anti-340B editorial.
The AHA asks that as the Senate begins drafting the FY 2027 appropriations bill, it funds health care programs that have proven successful in improving access to quality health care for patients and communities across America.
The AHA asks that as the House begins drafting the FY 2027 appropriations bill, it funds health care programs that have proven successful in improving access to quality health care for patients and communities across America.
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to discounted drug prices unless they comply with new data submission requirements.
The American Hospital Association (AHA) writes to alert you to the latest development in connection with the growing number of drug company policies requiring covered entities to submit onerous amounts of claims data in exchange for their statutorily owed 340B discounts.